Literature DB >> 25914862

Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade.

Janis M Taube1.   

Abstract

Focal tumor cell PD-L1 expression adjacent to TIL can be used as a surrogate marker of an ongoing antitumor host response, which may be unleashed by PD-1 blockade. Tumor cell PD-L1 expression is superior to TIL PD-1 expression and the presence of TIL alone, when predicting response to anti-PD-1 therapy.

Entities:  

Keywords:  CRPC, castration-resistant prostate cancer; FFPE, formalin-fixed paraffin-embedded; NSCLC, non-small cell lung carcinoma; PD-1; PD-1, programmed death 1; PD-L1; PD-L1, programmed death-ligand 1; PD-L2; PD-L2, programmed death-ligand 2; RCC, renal cell carcinoma; TIL, tumor-infiltrating lymphocytes; cancer immunotherapy; tumor microenvironment

Year:  2014        PMID： 25914862      PMCID： PMC4292419          DOI： 10.4161/21624011.2014.963413

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  4 in total

1.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

2.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

3.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245
  4 in total
  41 in total

1.  Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Authors:  Laetitia Fend; Sylvie Rusakiewicz; Julien Adam; Bérangère Bastien; Anne Caignard; Meriem Messaoudene; Christina Iribarren; Isabelle Cremer; Aurélien Marabelle; Christophe Borg; Michaela Semeraro; Luc Barraud; Jean-Marc Limacher; Alexander Eggermont; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 2.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

3.  Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

4.  PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.

Authors:  Joel C Sunshine; Peter L Nguyen; Genevieve J Kaunitz; Tricia R Cottrell; Sneha Berry; Jessica Esandrio; Haiying Xu; Aleksandra Ogurtsova; Karen B Bleich; Toby C Cornish; Evan J Lipson; Robert A Anders; Janis M Taube
Journal:  Clin Cancer Res       Date:  2017-04-20       Impact factor: 12.531

5.  Doubling the blockade for melanoma immunotherapy.

Authors:  Lorenzo Galluzzi; Alexander Eggermont; Guido Kroemer
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 6.  PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.

Authors:  Tricia R Cottrell; Janis M Taube
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

7.  Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.

Authors:  Andrew Gabrielson; Yunan Wu; Hongkun Wang; Jiji Jiang; Bhaskar Kallakury; Zoran Gatalica; Sandeep Reddy; David Kleiner; Thomas Fishbein; Lynt Johnson; Eddie Island; Rohit Satoskar; Filip Banovac; Reena Jha; Jaydeep Kachhela; Perry Feng; Tiger Zhang; Anteneh Tesfaye; Petra Prins; Christopher Loffredo; John Marshall; Louis Weiner; Michael Atkins; Aiwu Ruth He
Journal:  Cancer Immunol Res       Date:  2016-03-11       Impact factor: 11.151

8.  PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.

Authors:  Andreas H Scheel; Sascha Ansén; Anne M Schultheis; Matthias Scheffler; Rieke N Fischer; Sebastian Michels; Martin Hellmich; Julie George; Thomas Zander; Michael Brockmann; Erich Stoelben; Harry Groen; Wim Timens; Sven Perner; Michael von Bergwelt-Baildon; Reinhard Büttner; Jürgen Wolf
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

Review 9.  Molecular diagnostics of lung cancer in the clinic.

Authors:  Lynette Sholl
Journal:  Transl Lung Cancer Res       Date:  2017-10

10.  A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.

Authors:  Xiao-Yan Hu; Wei Zhang; Yue Hu; Yong Zhang; Rui Gong; Jin-Yan Liang; Li Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.